TY - JOUR
T1 - Isoform-specific modulation of coronary artery PKC by glucocorticoids
AU - Maddali, K. K.
AU - Korzick, D. H.
AU - Turk, J. R.
AU - Bowles, D. K.
N1 - Funding Information:
This work was supported by NIH HL52490 and NASA (D.K.B. and J.R.T.) and NIH KO1 AG00875 (D.H.K.).
PY - 2005/3
Y1 - 2005/3
N2 - Glucocorticoids (GC) exert diverse cellular effects in response to both acute and chronic stress, the functional consequences of which have been implicated in the development of cardiovascular pathology such as hypertension and atherosclerosis. However, the mechanisms by which GCs activate divergent signaling pathways are poorly understood. The present study examined the direct effects of natural (cortisol) and synthetic (dexamethasone) GCs on protein kinase C (PKC) isoform expression in coronary arteries. Porcine right coronary arteries were treated in vitro for 18 h in the presence and absence of either dexamethasone (10, 100, or 500 nM) or cortisol (50, 125, 250, or 500 nM). PKC isoform levels and subcellular distribution were determined by immmunoblotting of whole cell homogenates and immunocytofluorescence using PKC-α, -βII, -ε, -δ, and -ζ specific antibodies. Dexamethasone caused a ∼4-fold increase in PKC-α, a ∼2.5-fold increase in PKC-βII, and a 2-fold increase in PKC-ε (p < 0.05). In contrast, dexamethasone had no effect on PKC-δ or PKC- ζ levels. Dexamethasone also caused an increase in the activity of PKC-α (285%), -βII (170%), and -ε (210%). Cortisol produced similar effects on PKC isoform expression. Confocal microscopy revealed that while dexamethasone altered localization patterns for PKC-α, -βII, and -ε, no such effect was observed for PKC-δ or PKC-ζ. The stimulatory effects of dexamethasone and cortisol on coronary PKC levels and translocation were prevented by the GC receptor (GR) blocker, RU486. These results demonstrate, for the first time, that GCs modulate coronary PKC expression and subcellular distribution in an isoform-specific manner through a GR-dependent mechanism.
AB - Glucocorticoids (GC) exert diverse cellular effects in response to both acute and chronic stress, the functional consequences of which have been implicated in the development of cardiovascular pathology such as hypertension and atherosclerosis. However, the mechanisms by which GCs activate divergent signaling pathways are poorly understood. The present study examined the direct effects of natural (cortisol) and synthetic (dexamethasone) GCs on protein kinase C (PKC) isoform expression in coronary arteries. Porcine right coronary arteries were treated in vitro for 18 h in the presence and absence of either dexamethasone (10, 100, or 500 nM) or cortisol (50, 125, 250, or 500 nM). PKC isoform levels and subcellular distribution were determined by immmunoblotting of whole cell homogenates and immunocytofluorescence using PKC-α, -βII, -ε, -δ, and -ζ specific antibodies. Dexamethasone caused a ∼4-fold increase in PKC-α, a ∼2.5-fold increase in PKC-βII, and a 2-fold increase in PKC-ε (p < 0.05). In contrast, dexamethasone had no effect on PKC-δ or PKC- ζ levels. Dexamethasone also caused an increase in the activity of PKC-α (285%), -βII (170%), and -ε (210%). Cortisol produced similar effects on PKC isoform expression. Confocal microscopy revealed that while dexamethasone altered localization patterns for PKC-α, -βII, and -ε, no such effect was observed for PKC-δ or PKC-ζ. The stimulatory effects of dexamethasone and cortisol on coronary PKC levels and translocation were prevented by the GC receptor (GR) blocker, RU486. These results demonstrate, for the first time, that GCs modulate coronary PKC expression and subcellular distribution in an isoform-specific manner through a GR-dependent mechanism.
UR - http://www.scopus.com/inward/record.url?scp=16244389342&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=16244389342&partnerID=8YFLogxK
U2 - 10.1016/j.vph.2004.11.008
DO - 10.1016/j.vph.2004.11.008
M3 - Article
C2 - 15820441
AN - SCOPUS:16244389342
SN - 1537-1891
VL - 42
SP - 153
EP - 162
JO - Vascular Pharmacology
JF - Vascular Pharmacology
IS - 4
ER -